ACRO Biomedical Co., Ltd. (TPEX:6748)
187.50
-8.00 (-4.09%)
Jul 9, 2026, 1:05 PM CST
ACRO Biomedical Revenue
In the year 2025, ACRO Biomedical had annual revenue of 38.26M TWD, down -13.51%. ACRO Biomedical had revenue of 24.94M in the half year ending December 31, 2025, a decrease of -29.27%.
Revenue
38.26M
Revenue Growth
-13.51%
P/S Ratio
346.27
Revenue / Employee
n/a
Employees
n/a
Market Cap
13.25B
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 38.26M | -5.98M | -13.51% |
| Dec 31, 2024 | 44.23M | -6.83M | -13.38% |
| Dec 31, 2023 | 51.06M | 23.43M | 84.79% |
| Dec 31, 2022 | 27.63M | 5.81M | 26.59% |
| Dec 31, 2021 | 21.83M | 3.80M | 21.04% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| EirGenix | 1.13B |
| Ever Supreme Bio Technology | 1.03B |
| PharmaEngine | 963.83M |
| Medigen Vaccine Biologics | 603.68M |
| TaiMed Biologics | 601.19M |
| Tanvex BioPharma | 483.94M |
| Polaris Group | 69.27M |
| Gongwin Biopharm Holdings | 38.28M |